The firm's own executives, plus two investors, bought additional equity.
FORT MYERS — NeoGenomics Inc. (symbol: NGNM.ob) announced today that it recently raised $3 million in additional equity. The company received its new capital as the result of an equity sale, in which just seven people participated.
Specifically, five members of the NeoGenomics board, plus two investors with an existing relationship with the firm, together bought 2 million shares of NeoGenomics stock for $3 million. No warrants were issued in the deal, and no placement agent was used, a release explained.
The NeoGenomics board has nine directors, according to the company's website. They are: Douglas Van Oort (executive chairman and CEO), Robert Gasparini (president and chief scientific officer), Dr. Michael Dent, Steven Jones, George O'Leary, Peter Peterson, William Robison, Dr. Marvin Jaffe, and Kevin Johnson.
The capital will help NeoGenomics “strengthen its financial position and fund growth initiatives,” the release said.
NeoGenomics specializes in cancer genetics diagnostic testing. The Fort Myers-based lab has additional facilities in Nashville, Tenn. and Irvine, Calif.